Abeona Therapeutics, founded in New York City, focuses on developing gene therapies for severe childhood diseases, including Sanfilippo Syndrome Types A and B. The company leverages its expertise in manufacturing, delivery, development, and discovery of novel gene and cell therapies. Abeona's robust pipeline includes advanced AAV capsids and therapies such as prademagene zamikeracel for RDEB and ABO-50X for genetic eye disorders. Their fully operational manufacturing facility supports both preclinical and clinical studies.
Notable affiliated individuals include scientific advisors and researchers specializing in gene therapy. Abeona has attracted significant investment from biotech-focused venture capital firms. Key achievements include the submission of a Biologics License Application (BLA) for prademagene zamikeracel and advancements in their genetic eye disorder treatments. Abeona's impact is marked by its innovative approach to addressing unmet medical needs in pediatric genetic disorders, positioning it as a leader in the gene therapy space.
Abeona Therapeutics' most recent funding round was for $20M (USD) in January 2024.
As of Jan 8, 2024, Abeona Therapeutics has disclosed funding of $354.7M (USD).

CLINUVEL

ALX Oncology

Armata Pharmaceuticals

Scancell

Biomm

Upstream Bio

Jagsonpal Pharma

Sionna Therapeutics

Innate Pharma

IMBiologics

Orphazyme

Apertura Gene Therapy
aperturagtx.com

Neurogene
neurogene.com

Affinia Therapeutics
affiniatx.com

bluebird bio
bluebirdbio.com

Greenland Mines
anewmeds.com

Capsida Biotherapeutics
capsida.com

NabGen
nabgen.com

Frontera Therapeutics

Krystal Biotech
krystalbio.com

Abeona Therapeutics, a NYC-based medical organization, develops gene therapies for deadly childhood diseases and manufactures next-gen AAV capsids.